Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Front-line treatment of CLL in the era of novel agents.

Robak T, Stilgenbauer S, Tedeschi A.

Cancer Treat Rev. 2017 Feb;53:70-78. doi: 10.1016/j.ctrv.2016.12.007. Epub 2016 Dec 30. Review.

PMID:
28081486
2.

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM.

J Clin Oncol. 2014 Sep 20;32(27):3039-47. Review.

3.

Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.

Molica S.

Expert Rev Hematol. 2015 Jun;8(3):277-81. doi: 10.1586/17474086.2015.1029450. Epub 2015 Mar 25.

PMID:
25804936
4.

Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.

Dias AL, Jain D.

Cardiovasc Hematol Agents Med Chem. 2013 Dec;11(4):265-71. Review.

5.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.

PMID:
28453705
6.

The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.

Tran PN, O'Brien S.

Expert Opin Drug Saf. 2017 Sep;16(9):1079-1088. doi: 10.1080/14740338.2017.1344213. Epub 2017 Jun 23. Review.

PMID:
28627951
7.

Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.

Sanford DS, Wierda WG, Burger JA, Keating MJ, O'Brien SM.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):385-91. doi: 10.1016/j.clml.2015.02.019. Epub 2015 Feb 19. Review.

8.

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.

Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, James D, Doyle M, Bari S, Zhuang SH.

Ann N Y Acad Sci. 2015 Nov;1358:82-94. doi: 10.1111/nyas.12878. Epub 2015 Sep 8. Review.

PMID:
26348626
9.

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV.

Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Review.

10.

The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.

Aw A, Brown JR.

Leuk Lymphoma. 2017 Oct;58(10):2287-2297. doi: 10.1080/10428194.2017.1312387. Epub 2017 May 9.

PMID:
28482721
11.

[Ibrutinib - new tool in hematologist hand, new challenges for internist].

Majcherek M, Dworacka M, Dworacki G.

Wiad Lek. 2017;70(1):92-95. Review. Polish.

PMID:
28343201
12.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S.

N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

13.

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Davids MS, Brown JR.

Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51. Review.

14.

Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.

Shanafelt TD, Borah BJ, Finnes HD, Chaffee KG, Ding W, Leis JF, Chanan-Khan AA, Parikh SA, Slager SL, Kay NE, Call TG.

J Oncol Pract. 2015 May;11(3):252-8. doi: 10.1200/JOP.2014.002469. Epub 2015 Mar 24.

PMID:
25804983
15.
16.

Ibrutinib in B lymphoid malignancies.

Smith MR.

Expert Opin Pharmacother. 2015;16(12):1879-87. doi: 10.1517/14656566.2015.1067302. Epub 2015 Jul 13. Review.

PMID:
26165513
17.

A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.

Lee CS, Rattu MA, Kim SS.

J Oncol Pharm Pract. 2016 Feb;22(1):92-104. doi: 10.1177/1078155214561281. Epub 2014 Nov 25. Review.

PMID:
25425007
18.

Ibrutinib: first global approval.

Cameron F, Sanford M.

Drugs. 2014 Feb;74(2):263-71. doi: 10.1007/s40265-014-0178-8. Review.

PMID:
24464309
19.

Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.

Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S.

Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954. Review.

PMID:
27252989
20.

Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.

Jain N, O'Brien S.

Hematol Oncol Clin North Am. 2013 Aug;27(4):851-60, x. doi: 10.1016/j.hoc.2013.01.006. Review.

Supplemental Content

Support Center